What next for deal-making in 2016?
There has been plenty of deal-making in the UK and record merger and acquisition (M&A) activity in the USA.
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 51 of 55
Archive
Brokers: Miners will have to dig deeper in 2016
Miners, Restaurant Group, AstraZeneca, Bovis
Thursday's trending - pharma, Fed rates and Astrazeneca
The Fed and pharma world were among the trending stories of the day.....
FTSE100 climbs; Paddy Power-Betfair gets the green light
Leading the way on the index was Standard Chartered
Investments and investor services
FTSE100 rises following the Fed's interest rate hike
In the UK, the FTSE100 had that feel-good feeling following the Fed hike
AstraZeneca buys cancer drug developer for US$4bn
Drug group is buying 55% interest in Acerta Pharma
FTSE rises; Supergroup makes a super start to the year
The FTSE100, which is down around 7.5% on the year, rose almost 1%, or 59 points, to 6,076 by lunch.
Shares rise on takeover activity and US rate hike prospects
FTSE 100 Index rose as investors brace for the first US interest rise in almost a decade.
Investments and investor services
FTSE100 drops as miners weigh...again
The miners were again at the bottom of the index, as a lower oil price weighed on metal prices.
FTSE100 flat; CityFibre to take on BT Openreach
The FTSE100 was three points lower at lunch at 5,949.
AstraZeneca in deal talks with Acerta Pharma
Last week, reports said the pharma giant was in “advanced talks” to buy Acerta for around US$5bn
South Africans lead FTSE 100 rebound
After heavy losses Friday, FTSE 100 added 48 to 6,001
Investments and investor services
Brokers: Mixed day for the retailers
Dixons Carphone and Dunelm were given the thumbs up, while Kingfisher and next were downgraded by broker Nomura
Investments and investor services
FTSE100 gains 25, Shire rises on M&A chatter
The FTSE100 could only manage a 25 point gain to 6,420.
AstraZeneca gets big upgrade from Morgan Stanley
Shares in big cap pharma AstraZeneca gained ground midweek as heavyweight broker Morgan Stanley said the sector was now fairly valued.
FTSE 100 consolidates early gains
FTSE 100 was 21 points higher at 6,416 ahed of the US opening
Pfizer agrees US$150bn Allergan merger
The combined group will become the world’s largest drug company.
Investors urged to take closer look at Astra’s lupus drug trial
AstraZeneca, Premier Oil, Man Group, and Genus are in the broker spotlight on Thursday
M&A boom looms in life science industry
Some 94% of companies in a survey plan to make acquisitions in the coming year